Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease
November 10 2021 - 7:00AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental disorders including Alzheimer’s disease,
Parkinson’s disease, Rett syndrome and other central nervous system
(CNS) diseases, today announced that its President and Chief
Executive Officer, Christopher U. Missling, PhD, will join the
panel, “Exploring the Promise of Novel Therapeutic Approaches,” at
the Lausanne VIII Workshop on Wednesday, November 17th at 10:00
a.m. EST to 11:00 a.m. EST.
The 2021 Lausanne Workshop for Leaders and
Innovators in Alzheimer’s is the eighth in a series of
Lausanne-based annual Alzheimer’s convenings with a goal to stop
Alzheimer’s by 2025. Over the past seven years, the Workshop has
become a highly-curated platform for global Alzheimer’s
stakeholders to identify challenges, set solution paths, measure
progress and hold each other accountable to act.
The Lausanne Workshop is organized under the
auspices of the Organisation for Economic Co-Operation and
Development (OECD) and supported by The Global CEO Initiative on
Alzheimer’s Disease (CEOi), Alzheimer’s Disease International (ADI)
and World Economic Forum (WEF). It launched in 2014 as a response
to the international call to action to stop dementia by 2025.
Click here to register or to learn more about
the event.
About Alzheimer’s Disease
Alzheimer’s disease is a progressive
degenerative brain disorder that gradually destroys a person's
memory and ability to learn, reason, make judgments, communicate
and carry out daily activities. An estimated 5.7 million Americans
currently have Alzheimer's dementia. Alzheimer’s is the most
common cause of dementia among older adults and is estimated to
rank as the third leading cause of death for older people in the
United States, just behind heart disease and cancer. In 2020,
Alzheimer's and other dementias cost the nation $305 billion. By
2050, these costs could rise as high as $1.1 trillion.1 There are
currently over 50 million people living with dementia around the
world, with numbers expected to increase to nearly 152 million by
2050.2 Almost 10 million new cases of dementia are diagnosed each
year worldwide, implying one new case every 3 seconds, and a
significant increase in the caregiving burden placed on society and
families.3
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental disorders including
Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other
central nervous system (CNS) diseases, pain, and various types of
cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine),
successfully completed a Phase 2a clinical trial for Alzheimer’s
disease and recently a Phase 2 proof-of-concept study in
Parkinson’s disease dementia and a Phase 2 study in adult patients
with Rett syndrome. ANAVEX®2-73 is an orally available drug
candidate that restores cellular homeostasis by targeting sigma-1
and muscarinic receptors. Preclinical studies demonstrated its
potential to halt and/or reverse the course of Alzheimer’s disease.
ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic,
neuroprotective, and anti-depressant properties in animal models,
indicating its potential to treat additional CNS disorders,
including epilepsy. The Michael J. Fox Foundation for Parkinson’s
Research previously awarded Anavex a research grant, which fully
funded a preclinical study to develop ANAVEX®2-73 for the treatment
of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and
muscarinic receptors, is a promising clinical stage drug candidate
demonstrating disease-modifying activity against the major
hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice,
including cognitive deficits, amyloid, and tau pathologies. In
preclinical trials, ANAVEX®3-71 has shown beneficial effects on
mitochondrial dysfunction and neuroinflammation. Further
information is available at www.anavex.com. You can also connect
with the company on Twitter, Facebook, Instagram and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.Research &
Business DevelopmentToll-free: 1-844-689-3939Email:
info@anavex.com
Investors:Andrew J.
BarwickiInvestor RelationsTel: 516-662-9461Email:
andrew@barwicki.com
_______________________
1 https://www.nia.nih.gov/health/alzheimers;
https://www.alz.org/alzheimers-dementia/facts-figures.2 Alzheimer's
Disease International. World Alzheimer Report 2019.
https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf.3 AARP.
2020 Report: Caregiving in the U.S.
https://www.aarp.org/content/dam/aarp/ppi/2020/05/full-report-caregiving-in-the-united-states.doi.10.26419-2Fppi.00103.001.pdf.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024